Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
0 hedge funds and large institutions have $0 invested in Progenics Pharmaceuticals Inc in 2020 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $177K → $0 (-$177K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Everence Capital Management
Goshen,
Indiana
|
-$123K |
| 2 |
New York State Teachers Retirement System (NYSTRS)
Albany,
New York
|
-$52K |
| 3 |
Daiwa Securities Group
Tokyo,
Japan
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
New York State Teachers Retirement System (NYSTRS)
Albany,
New York
| – | -$52K | -138,663 | Closed |
|
|
ECM
2
Everence Capital Management
Goshen,
Indiana
| – | -$123K | -28,980 | Closed |
|
|
3
Daiwa Securities Group
Tokyo,
Japan
| – | -$2K | -533 | Closed |
|
PGNX Hedge Fund Activity: Q3 2020 in Review
0 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2020, worth a combined $0 — down 100% from $177K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PGNX and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Everence Capital Management, exiting entirely with an estimated $123K sold.
- 0 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2020, down from 3 in Q2 2020.
- Funds reported $0 of Progenics Pharmaceuticals Inc stock for Q3 2020, down 100% quarter-over-quarter.
- 0 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2020 and 3 closed out, a net change of -3 holders.
- The largest Progenics Pharmaceuticals Inc seller in Q3 2020 was Everence Capital Management, an estimated $123K sold.
Based on aggregated 13F filings for Q3 2020.